Alan S. Brown

Alan S. Brown

Auto-generated profile, based on publicly available information

Alan S. Brown

Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY (Brown and Cheslack-Postava); Department of Epidemiology, Columbia University, Mailman School of Public Health, New York, NY (Brown)

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2012
Verified
Book
Closed access
PDF file
ABAlan S. Brown
Alan S. Brown
This book brings together the body of empirical findings and theoretical interpretations of the tip of the tongue (TOT) experience – when a well-known or familiar word cannot immediately be recalled. Although research has been published on TOTs for over a century, the experience retains its fascination for both cognitive and linguistic researchers. After a review of various research procedures used to study TOTs, the book offers a summary of attempts to manipulate this rare cognitive experience through cue and prime procedures. Various aspects of the inaccessible target word are frequently available – such as first letter and syllable number – even in the absence of actual retrieval, and the book explores the implications of these bits of target-word information for mechanisms for word storage and retrieval. It also examines: what characteristics of a word make it potentially more vulnerable to a TOT; why words related to the target word (called "interlopers") often come to mind; the recovery process, when the momentarily-inaccessible word is recovered shortly after the TOT is first experienced; and efforts to evaluate individual differences in the likelihood to experience TOTs.

21 July 2021 in Biological Psychiatry
Verified
Journal Article
Closed access
ASAndre Sourander
Andre Sourander
SUSubina Upadhyaya
Subina Upadhyaya
HSHeljä-Marja Surcel
Heljä-Marja Surcel
SHSusanna Hinkka-Yli-Salomäki
Susanna Hinkka-Yli-Salomäki
KCKeely Cheslack-Postava
Keely Cheslack-Postava
ABAlan S. Brown
Alan S. Brown

1 December 2004 in Current Directions in Psychological Science
Verified
Journal Article
Closed access
PDF file
ABAlan S. Brown
Alan S. Brown

19 March 2022 in Environmental Research
Verified
Journal Article
Closed access
KCKeely Cheslack-Postava
Keely Cheslack-Postava
PRPanu Rantakokko
Panu Rantakokko
HKHannu Kiviranta
Hannu Kiviranta
SHSusanna Hinkka-Yli-Salomäki
Susanna Hinkka-Yli-Salomäki
HSHeljä-Marja Surcel
Heljä-Marja Surcel
ABAlan S. Brown
Alan S. Brown

1 August 2011 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
DFDavid Freedman
David Freedman
RDRaymond Deicken
Raymond Deicken
LKLawrence S. Kegeles
Lawrence S. Kegeles
SVSophia Vinogradov
Sophia Vinogradov
YBYuanyuan Bao
Yuanyuan Bao
ABAlan S. Brown
Alan S. Brown
Prior research has shown that maternal-fetal Rhesus (Rh) and ABO blood incompatibility increase the risk for schizophrenia. In the present study, the relationship between blood incompatibility and volumes of brain structures previously implicated in schizophrenia was assessed in schizophrenia cases and controls from a large birth cohort. Rh/ABO incompatible cases had significantly reduced cortical gray matter volume compared to compatible cases, a finding which appears to be driven by significant volume reductions in the dorsolateral prefrontal cortex and inferior frontal cortex. Larger hippocampal and putamen volumes were also observed in exposed controls compared to unexposed controls. Although the sample size is small and replications are required, these data suggest that maternal-fetal blood incompatibility may increase the risk for altered brain morphology in both schizophrenia and in controls. The findings also suggest that the larger hippocampal volume in exposed controls may indicate a mechanism of adaptive resilience which diminishes the risk that controls will develop schizophrenia.

5 February 2026 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Open access
HMHeli Malm
Heli Malm
ABAlan S. Brown
Alan S. Brown
KCKeely Cheslack-Postava
Keely Cheslack-Postava
MGMika Gissler
Mika Gissler
DGDavid Gyllenberg
David Gyllenberg
ASAndre Sourander
Andre Sourander
Maternal underlying depression may confound previously reported associations between selective serotonin reuptake inhibitor (SSRI) use and adverse pregnancy and neonatal outcomes. To determine whether SSRI use during pregnancy is associated with an increased risk of pregnancy and neonatal complications after adjusting for indicators of maternal depression severity. This population-based birth cohort study used data from national registers in Finland and included 1272,587 singleton live births from 1996 to 2018. Pregnancy outcome of women with two or more SSRI purchases during pregnancy (N=19,020) were compared to women with a diagnosis of depression but no antidepressant use (N=19,625), and women who discontinued SSRIs before pregnancy (n=3145). Analyses included adjustment for several indicators of depression severity and within-family sibling comparisons. After adjusting for confounders and comparing to women with depression who did not use antidepressants, maternal SSRI use was associated with an increased risk of gestational diabetes (OR 1.14; 95% CI 1.07-1.22), while the risk of cesarean section (CS), late (32-36+6 weeks' gestation) and very preterm birth (<32 weeks' gestation), small for gestational age, and low and very low birth weight was lower. Among SSRI-exposed infants, risk of a low (<7) 5-minute Apgar score (OR 2.02; 95% CI 1.78-2.30), breathing problems (OR 1.61; 95% CI 1.48-1.75), and neonatal care unit (NCU) treatment (OR 1.23; 95% CI 1.16-1.31) was higher, whereas the risk of hospital stay at 7 days and major congenital anomalies was lower. Third-trimester exposure further increased the risk of a low 5-minute Apgar score (OR 3.44; 95% CI 2.93-4.04). After adjustment for indicators of depression severity, the increased risk of gestational diabetes persisted (OR 1.20; 95% CI 1.09-1.32), as did the lower risk of CS, very preterm birth, and low and very low birth weight, and the risks of a low 5-minute Apgar score, breathing problems, and NCU treatment remained higher. Compared to women who discontinued SSRI use before pregnancy, SSRI use was associated with lower risks of late preterm birth and low birth weight (OR 0.83; 95% CI 0.70-0.999 and OR 0.78; 95% CI 0.64-0.96, respectively), while the neonatal risks described above remained elevated. In the sibling-pair analysis, SSRI use was associated with an increased risk of gestational diabetes and neonatal complications other than malformations, including an increased risk of needing hospital stay at 7 days of age. SSRI use during pregnancy affects neonatal health beyond maternal depression by increasing symptoms related to delayed neonatal adaptation, although it may reduce the risk of preterm birth. The observed increase in the risk of gestational diabetes warrants further study. VIDEO